Compare RYZ & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | PHAR |
|---|---|---|
| Founded | 1842 | 1988 |
| Country | United States | Netherlands |
| Employees | 4300 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2014 | 2020 |
| Metric | RYZ | PHAR |
|---|---|---|
| Price | $26.61 | $12.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 333.3K | 10.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $75.79 | $10.04 |
| Revenue Next Year | $2.17 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.34 | $9.54 |
| 52 Week High | $29.03 | $21.34 |
| Indicator | RYZ | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 31.19 |
| Support Level | $23.60 | $11.43 |
| Resistance Level | $29.03 | $17.41 |
| Average True Range (ATR) | 1.38 | 0.53 |
| MACD | -0.17 | -0.09 |
| Stochastic Oscillator | 56.10 | 15.28 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.